Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734313 · ClinicalTrials.gov registry record · NA
Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression
A NA study of Diabetes and Type 1 Diabetes, sponsored by Albert Einstein College of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 94
- Enrollment target
- 2
- Study locations
NCT05734313: Recruiting NA study of Diabetes and Type 1 Diabetes, sponsored by Albert Einstein College of Medicine.
NCT05734313 is a NA study of Diabetes and Type 1 Diabetes that is actively recruiting participants, run by Albert Einstein College of Medicine. The registered enrollment target is 94 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05734313, a NA study of Diabetes and Type 1 Diabetes, is actively recruiting participants, sponsored by Albert Einstein College of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 94 participants
- Enrollment target
- 2
- Study locations
Study Summary
This project will evaluate a telemedicine-delivered, Unified Protocol for Cognitive-Behavioral Therapy (UP-CBT) enhanced with continuous glucose monitor (CGM) review to target anxiety and depressive symptoms and glycemic control in adults with type 1 diabetes.
Primary Outcome
Participant ratings will be conducted via video conference by clinicians blinded to the condition, using the Structured Interview Guide for the Hamilton Anxiety Rating Scales (SIGH-A). SIGH-A measures the severity of a patient's somatic and psychic anxiety based on 14 parameters including anxious mood, tension, fears, insomnia, somatic complaints and behavior at the interview. Each item is assigned a 5-point score ranging from 0 (not present) to 4 (severe) yielding an overall possible score of 0
Conditions Studied
Interventions
- DEVICE Continuous Glucose Monitoring (CGM)
- BEHAVIORAL Unified protocol for cognitive behavioral therapy (UP-CBT)
Study Locations (2)
Massachusetts
- Boston University - Boston
New York
- Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT05734313 shows while recruiting
NCT05734313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Continuous Glucose Monitoring (CGM) is the first listed.
NCT05734313 reports a single indexed study location in Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05734313 about?
NCT05734313 is a clinical study titled "Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression". This project will evaluate a telemedicine-delivered, Unified Protocol for Cognitive-Behavioral Therapy (UP-CBT) enhanced with continuous glucose monitor (CGM) review to target anxiety and depressive symptoms and glycemic control in adults with type 1 diabetes.
What is the current status of trial NCT05734313?
This trial is currently recruiting. It is a NA study. The enrollment target is 94 participants. The study started on 2023-03-31. Estimated completion is 2027-12.
What conditions does trial NCT05734313 study?
This clinical trial studies the following conditions: Diabetes, Type 1 Diabetes.
What interventions are being tested in trial NCT05734313?
The interventions under investigation include: Continuous Glucose Monitoring (CGM) (DEVICE), Unified protocol for cognitive behavioral therapy (UP-CBT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05734313?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734313 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05734313's enrollment target sits among peer trials
94 199th of 338 higher than 140 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI